Table 6 The independent variables that influence the glucose improvement.
Parameters | Improved | Unimproved | OR (95%CI) | P - valuea |
|---|---|---|---|---|
(N = 182) | (N = 150) | |||
Sex (Ref-male) | 96(52.7%) | 77(51.3%) | 1 | |
Female | 86(47.3%) | 73(48.7%) | 0.656(0.325–1.324) | 0.239 |
Age, years (Ref-<44) | 54(29.7%) | 23(15.3%) | 1 | |
≥44 and <51 | 40(22%) | 38(25.3%) | 2.038(0.921–4.510) | 0.079 |
≥51 and <61 | 47(25.8%) | 43(28.7%) | 1.792(0.787–4.082) | 0.165 |
≥61 | 41(22.5%) | 46(30.7%) | 2.816(1.217–6.513) | 0.016b |
Genotype (Ref-1) | 157(86.3%) | 129(86%) | 1 | |
2 | 7(3.8%) | 4(2.7%) | 1.378(0.408–4.652) | 0.605 |
3 | 16(8.8%) | 11(7.3%) | 1.066(0.479–2.375) | 0.875 |
Others and unknown | 1(0.5%) | 1(0.7%) | 0.733(0.431–1.246) | 0.251 |
HCV-RNA, log IU/mL (Ref<5.17) | 53(29.1%) | 29(19.3%) | 1 | |
≥5.17 and <6.07 | 39(21.4%) | 44(29.3%) | 1.848(0.854–3.998) | 0.119 |
≥6.07 and <6.55 | 44(24.2%) | 38(25.3%) | 2.005(0.888–4.525) | 0.094 |
≥6.55 | 46(25.3%) | 39(26%) | 2.359(1.061–5.247) | 0.035b |
FPG, mmol/L (Ref-<5.84) | 60(33%) | 23(15.3%) | 1 | |
≥5.84 and <6.22 | 46(25.3%) | 37(24.7%) | 2.962(1.358–6.464) | 0.006b |
≥6.22 and <6.94 | 33(18.1%) | 50(33.3%) | 4.540(2.074–9.941) | <0.001b |
≥6.94 | 43(23.7%) | 40(26.7%) | 3.325(1.479–7.471) | 0.004b |
TBiL, mmol/L (Ref-<11.82) | 43(23.6%) | 40(26.7%) | 1 | |
≥11.82 and <16.65 | 58(31.9%) | 25(16.7%) | 1.056(0.364–3.064) | 0.921 |
≥16.65 and <21.67 | 42(23.1%) | 41(27.3%) | 3.763(1.027–13.794) | 0.046b |
≥21.67 | 39(21.4%) | 44(29.3%) | 5.010(1.150–21.832) | 0.032b |
ALT, IU/L (Ref-<33.00) | 49(26.9%) | 33(22%) | 1 | |
≥33.0 and <56.50 | 43(23.6%) | 41(27.3%) | 1.908(0.735–4.954) | 0.184 |
≥56.50 and <110.75 | 49(26.9%) | 34(22.7%) | 1.952(0.663–5.747) | 0.224 |
≥110.75 | 41(22.5%) | 42(28%) | 4.468(1.126–17.729) | 0.033b |
AST, IU/L (Ref-<33.00) | 45(24.7%) | 33(22%) | 1 | |
≥33.00 and 54.00 | 48(26.4%) | 39(26%) | 0.684(0.259–1.808) | 0.444 |
≥54.00 and 90.00 | 46(25.3%) | 37(24.7%) | 0.532(0.164–1.729) | 0.294 |
≥90.00 | 43(23.6%) | 41(27.3%) | 0.330(0.067–1.620) | 0.172 |
ALB, g/L (Ref-<40.72) | 41(22.5%) | 42(28%) | 1 | |
≥40.72 and <43.80 | 46(25.3%) | 34(22.7%) | 0.608(0.276–1.339) | 0.217 |
≥43.80 and <46.60 | 46(25.3%) | 38(25.3%) | 0.817(0.365–1.828) | 0.622 |
≥46.60 | 49(26.9%) | 36(24%) | 0.651(0.288–1.473) | 0.303 |
ALP, IU/L (Ref-<69.00) | 48(26.4%) | 34(22.7%) | 1 | |
≥69.00 and <85.00 | 52(28.6%) | 30(20%) | 0.673(0.308–1.471) | 0.321 |
≥85.00 and <110.00 | 47(25.8%) | 36(24%) | 1.084(0.501–2.348) | 0.838 |
≥110.00 | 35(19.2%) | 50(33.3%) | 2.104(0.863–5.126) | 0.102 |
GGT, IU/L (Ref<26.00) | 45(24.7%) | 37(24.7%) | 1 | |
≥26.00 and <41.50 | 45(24.7%) | 39(26%) | 0.628(0.286–1.382) | 0.248 |
≥41.50 and <93.25 | 49(26.9%) | 34(22.7%) | 0.476(0.196–1.156) | 0.101 |
≥93.25 | 43(23.6%) | 40(26.7%) | 0.587(0.211–1.630) | 0.306 |
Hb, g/L (Ref-<26) | 42(23.1%) | 39(26%) | 1 | |
≥26 and <141 | 44(24.2%) | 40(26.7%) | 1.245(0.570–2.720) | 0.582 |
≥141 and <153 | 46(25.3%) | 31(20.7%) | 0.761(0.315–1.837) | 0.544 |
≥153 | 50(27.5%) | 40(26.7%) | 1.111(0.407–3.033) | 0.838 |
PLTs, 109/L (Ref<77.25) | 35(19.2%) | 48(32%) | 1 | |
≥77.25 and <114.00 | 50(27.5%) | 32(21.3%) | 0.553(0.234–1.310) | 0.178 |
≥114.00 and <153.25 | 42(23.1%) | 42(28%) | 0.956(0.346–2.644) | 0.931 |
≥153.25 | 55(30.2%) | 28(18.7%) | 0.450(0.143–1.420) | 0.173 |
WBCs, 109/L (Ref-<4.132) | 38(20.9%) | 45(30%) | 1 | |
≥4.132 and <5.24 | 48(26.4%) | 34(22.7%) | 0.487(0.219–1.083) | 0.078 |
≥5.24 and <6.52 | 49(26.9%) | 35(23.3%) | 0.440(0.194–0.999) | 0.050 |
≥6.52 | 47(25.8%) | 36(24%) | 0.602(0.256–1.413) | 0.244 |
APRI (Ref- ≤ 2) | 130(71.4%) | 91(60.7%) | ||
>2 | 52(28.6%) | 59(39.3%) | 0.895(0.337–2.379) | 0.824 |
FIB-4 (Ref- ≤ 3.25) | 94(51.6) | 61(40.7%) | ||
>3.25 | 88(48.4) | 89(59.3%) | 1.219(0.481–3.090) | 0.676 |
